Program
07:30 – 08:30
Abstract Session
08:30 – 08:40
Opening & Welcome
08:40 – 10:15
Session 1. Evidence Update: Sublobar Resection vs Lobectomy (Stage IA)
08:40 – 08:55
What the Evidence Really Says in 2026: Sublobar vs Lobar for Stage IA NSCLC
Alan Sihoe (Gleneagles Hong Kong Hospital, Hong Kong)
08:55 – 09:10
Segmentectomy vs Wedge: When Does Anatomy Matter?
Yasuhiro Tsutani (Hiroshima University, Japan)
09:10 – 09:25
East vs West: Are We Treating the Same Disease Differently? Or different disease samely ?
Mong-Wei Lin (National Taiwan University Hospital, Taipei)
09:25 – 09:40
From Trials to Real World: Why Outcomes Diverge and What Surgeons Can Do
Haiquan Chen (Fudan Univ. Shanghai Cancer Center, China)
09:40- 09:55
Redefining the Limit: Japan and the Next Wave of Sublobar Resection RCTs
09:55 – 10:15
Panel Discussion
10:15 – 10:35
Coffee Break
10:35 – 12:10
Session 2. Patient Selection & ‘Red Flags’: how to decide?
10:35 – 10:50
Biology Overrides Size: Defining High-Risk Stage IA Beyond Diameter
10:50 – 11:05
Localization Strategies for Sublobar Resection: Matching Technique to Lesion
Hyun Koo Kim (Korea University Guro Hospital, Korea)
11:05 – 11:20
3D Planning: The Gatekeeper of the Right Segmentectomy
Karel Pfeuty (Hôpital Yves Le Foll, France)
11:20 – 11:35
Not All Segmentectomies Are Equal: Separating the Safe from the Risky
Agathe Seguin-Givelet (Ambroise Pare Hartman Private Hospital, Paris, France)
11:35 – 11:50
How Much Lung? AI-Driven Multimodal Models for the Lobectomy vs. Sublobar Decision
Gavin M Wright, University of Melbourne, Australia
11:50 – 12:10
Panel Discussion
12:10 – 13:20
Symposium 1
13:20 – 14:55
Session 3. Oncologic Quality in Sublobar Surgery: Margins, Nodes, Workflow
13:20 – 13:35
Margin Strategy in Practice: When to Extend, When to Convert
Yasuhiro Tsutani (Hiroshima University, Japan)
13:35 – 13:50
Tumor Size vs Margin Ratio: Myth or Rule?
Haiquan Chen (Fudan Univ. Shanghai Cancer Center, China)
13:50 – 14:05
STAS: Artifact or Enemy?” • The Pathologist: “STAS Doesn’t Exist” • The Surgeon: “STAS Will Change Your Operation”
Prasad S. Adusumilli (MSKCC, USA) Mr X pathologist Korea)
14:05 – 14:20
Nodal Staging During Segmentectomy: Minimal Requirements and Quality Metrics
Hong Kwan Kim (Samsung Medical Center, Korea)
14:20 – 14:35
When Sublobar Fails: Can We Rescue Oncologic Outcomes?
Hisashi Saji (St Marianna Univ. School of Medicine, Japan)
14:35 – 14:55
Panel Discussion
14:55 – 15:15
Coffee Break
15:15 – 16:50
Session 4. Outcomes Beyond Survival: PRO/QoL, Recovery, Surveillance
15:15 – 15:30
Pulmonary Function After Sublobar Resection: Do the Differences Last?
Gavin M Wright, University of Melbourne, Australia
15:30 – 15:45
JCOG0802: Local Recurrence, Competing Risks, and the Survival Paradox
Alan Sihoe (Gleneagles Hong Kong Hospital, Hong Kong)
15:45 – 16:00
Saving Lung for Later: Segmentectomy in Metachronous Early NSCLC
Karel Pfeuty (Hôpital Yves Le Foll, France)
16:00 – 16:15
Does Surgical Approach (VATS,RATS) Influence Patient-Centered Outcomes?
Seong-Yong Park (Samsung Medical Center, Korea)
16:15 – 16:30
Surveillance Strategy: Should We Follow Sublobar Patients Differently?
Hisashi Saji (St Marianna Univ. School of Medicine, Japan)
16:30 – 16:50
Panel Discussion
16:50 – 17:10
Detailed Session Outlines
07:30 – 08:30
Video Session
08:30 – 10:05
Session 5. TECHNICAL MASTERCLASS: Segmentectomy Step-by-Step (Standard → Complex)
08:30 – 08:45
Standard Segmentectomy — A Reproducible Step-by-Step Approach
Chang Young Lee (Yonsei University, Korea)
08:45 – 09:00
Complex Segmentectomy — Margin-First Strategies and Bail-Out Rules
Yin-Kai Chao (Chang Gung Memorial Hospital, Taiwan)
09:00 – 09:15
The Surgeon’s GPS: 3D Reconstruction as an Intraoperative Guide for Resection
Agathe Seguin-Givelet (Ambroise Pare Hartmann Private Hospital,Paris, France)
09:15 – 09:30
ICG Fluorescence for Intersegmental Plane Identification: Tips & Pitfalls
Calvin S. H. Ng (Chinese University of Hong Kong, Hong Kong)
09:30 – 09:45
Localization Strategies for Sublobar Resection: Matching Technique to Lesion
Hyun Koo Kim (Korea University Guro Hospital, Korea)
09:45 – 10:05
Panel Discussion
10:05 – 10:25
Coffee Break
10:25 – 12:00
Session 6. Platforms & Access: RATS vs VATS vs Open, Novel Approaches, Disparities
10:25 – 10:40
RATS vs VATS Segmentectomy: What Do We Gain — And at What Cost?
Woo Sik Yu (Ajou University Hospital)
10:40 – 10:55
Novel Access Routes (Subcostal / Outside-the-Cage): Feasibility & Safety
Yin-Kai Chao (Chang Gung Memorial Hospital, Taiwan)
10:55 – 11:10
Disparities & Implementation — European Perspective
Rene Petersen (Copenhagen Univ. Hospital, Denmark)
11:10 – 11:25
Disparities & Implementation — American Perspective
Janani Reisenauer (Mayo Clinic, USA)
11:25 – 11:40
Single-Port Robotic Segmentectomy: Evolution or Hype?
Hyun Koo Kim (Korea University Guro Hospital, Korea)
11:40 – 12:00
Panel Discussion
12:00 – 13:00
Symposium 2
13:00 – 14:20
Session 7. Elderly & High-Risk Patients: What is Feasible, What is Optimal?
13:00 – 13:15
Octogenarians: Choosing Extent and Approach Without Compromising Oncologic Principles
Rene Petersen (Copenhagen Univ. Hospital, Denmark)
13:15 – 13:30
Segmentectomy vs Wedge in the Elderly: Where Is the Evidence Going?
13:30 – 13:45
Frailty Should Drive Surgical Decision: How to Use it in Practicle?
13:45 – 14:00
SBRT vs Sublobar in High-Risk Patients: Who Should Get What?
Kelvin Lau (St Bartholomew’s Hospital, UK)
14:00 – 14:40
Panel Discussion
14:20 – 14:40
Coffee Break
14:40 – 16:15
Session 8. Dedicated Half-Day: Bronchoscopic Ablation (Endobronchial Therapy)
14:40 – 14:55
Who Should Receive Ablation Instead of Surgery
Janani Reisenauer (Mayo Clinic, USA)
14:55 – 15:10
Navigation & Robotic Bronchoscopy: Enabling Curative Ablation?
Calvin S. H. Ng (Chinese University of Hong Kong, Hong Kong)
15:10 – 15:25
Choosing the Right Energy: Matching Platforms to Tumor features
Michael Pritchett (FirstHealth Moore Regional, USA)
15:25 – 15:40
Oncologic Outcomes and Limitations of Bronchoscopic Ablation
Janani Reisenauer (Mayo Clinic, USA)
15:40 – 15:55
Hybrid Strategies: When to Combine Surgery and Ablation?
Kelvin Lau (St Bartholomew’s Hospital, UK)
15:55 – 16:15
Panel Discussion
16:15 – 16:35
Coffee Break
16:35 – 17:35
Session 9. Biology-Driven De-escalation: ctDNA, Radiomics/AI, Peri-op Systemic Therapy
16:35 – 16:50
ctDNA / MRD and Extent of Resection: Are We Ready for Biomarker-Guided Surgery?
Tae-Hee Hong (Yonsei University, Korea)
16:50 – 17:05
De-escalating Surgery After Neoadjuvant Chemo-IO: Is There a Role for Segmentectomy?
17:05 – 17:20
Can Systemic Therapy Replace Surgery in Very Early Stage?
17:20 – 17:35
Panel Discussion
17:35 – 17:45
Closing Remarks